Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (June 2017)
45 slides from Corbus Pharmaceuticals's investor presentation, Jun 7, 2017
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: Leadership Team
Leadership Team Management Yuval Cohen, PhD Chief Executive Officer, Director Co-founder and former President of Celsus Therapeutics (CLTX). Expertise in developing antiinflammatory drugs including for CF ‘Sean Moran, CPA, MBA Chief Financial Officer Former CFO: InVivo (NVIV), Gelsion (CLSN), Transp
Slide 4: Overview
x Overview Targeting Rare + Chronic + Serious Inflammatory / Fibrotic Diseases Anabasum: ¢ Novel synthetic oral endocannabinoid-mimetic with unique MOA ° 4 clinical programs ° Positive Phase 2 data: systemic sclerosis and cystic fibrosis ° Multiple opportunities to expand into additional indications
Slide 5: Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases
~ Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases Patient Phase of Orphan Fast Track Open-Label | Nondilutive inet iterd Population | Development | Designation Status Extension | Funding Revit Geils la >) Systemic Sclerosis 90,000 Launch Vv v V Commenc
Slide 6: Normal Inflammatory Process vs. Chronic Inflammation
Normal Inflammatory Process vs. Chronic Inflammation Normal Inflammation Process Activation Resolution Inflammation / Fibrosis Inflammation / Fibrosis Inflammatory / Fibrotic Disease Chronic Inflammation / Fibrosis Activation Time Immune System Returns to Homeostasis Time Immune System is Unable to
Slide 7: Endocannabinoids Play a Unique Role in Inflammation and Fibrosis
Endocannabinoids Play a Unique Role in Inflammation and Fibrosis oe * Short-lived on-demand lipid mediators produced by multiple cell types « Modulate innate immune responses! via cannabinoid receptor type 2 (CB2) on immune cells? * CB2 mouse knockouts have exaggerated innate immune responses and fi
Slide 8: Unique Characteristics of Anabasum Make It an Attractive Candidate
Y High *CB2 Binding Affinity (Pro-resolution receptors in the immune system) ( Low °CB1 Binding Affinity (Analgesic receptors in the brain) *Blood Brain Barrier Penetration > Unique Characteristics of Anabasum Make It an Attractive Candidate for Rare + Chronic Inflammatory / Fibrotic Diseases Target
Slide 9: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
’- Anabasum Promotes Resolution of Inflammation and Fibrotic Responses Resolution of Chronic Inflammation and Fibrosis Anabasum: Triggers Resolution of Innate Immune Responses v Pro-inflammatory lipids v Vasodilation / edema v Chemokines Y Pro-resolving lipid mediators ¥ Tissue infiltration with V P
Slide 10: Diffuse Cutaneous Systemic Sclerosis
Slide 11: Systemic Sclerosis
Systemic Sclerosis Chronic systemic autoimmune disease causing fibrosis of skin and internal organs Key Takeaways Life-threatening, rare disease (ob) No SSc-specific drugs approved Current therapy: AX Immunosuppressive agents (safety risk) Pacnus ecu MAME gue PeeeT 40-60 Years Average age of patient
Slide 12: Clinical Development of Anabasum in Systemic Sclerosis
x Clinical Development of Anabasum in Systemic Sclerosis ° Positive data in Phase 2 study ¢ Well tolerated and not immunosuppressive * Consistent clinical benefit in multiple efficacy outcomes ¢ Improvement of biomarkers in skin biopsies * Ongoing open-label extension of Phase 2 study ° Phase 3 stud
Slide 13: Design of Completed Phase 2 Study
x Design of Completed Phase 2 Study Positive Results Reported in November 2016 (— » * Double-blind, randomized, placebo-controlled Primary Endpoints: * 9 clinical sites in the U.S. * Safely and tolerability * ACR CRISS 43 adults ages 18 to 70 with SSc Secondary Endpoints: « ACR-CRISS domains: mRSS;
Slide 14: Safety and Tolerability Summary
x Safety and Tolerability Summary e« Anabasum was well tolerated « No serious or severe anabasum-related TEAEs noted ° Most common adverse events were mild/moderate: - Dizziness (22% in anabasum-treated subjects vs. 13% in placebo-treated subjects) - Fatigue (19% in anabasum-treated subjects vs. 7%
Slide 15: mRSS: Skin Thickening Improved
x mRSS: Skin Thickening Improved mRSS Change from Baseline Primary Endpoint in 7 ° © Anabasum —e—placebo Upcoming Phase 3 Study 0 e 1 * mRSS improved at week 16 from baseline -4.7 £7 + 1.1 (SE) for anabasum subjects vs. -2.0 + Y 2 1.5 for placebo subjects yg 2 3 * Improvement from baseline of -4.7 p
Slide 16: Improved Patient Reported Skin Symptoms
Improved Patient Reported Skin Symptoms { SSc Skin Symptoms Questionnaire? 5-D Itch Questionnaire? \ 0 ° s -10 2 -is 20 25 SD Itch score, change from baseline $Sc Skin Questionnaire score, change from baseline 25 P?=0.044 P=0.004 P? = 0.032 30 + 34 0 4 12 ) 4 2 Week Week —®- Anabasum —®=Placebo \ Re
Slide 17: Improvements in ACR-CRISS Scores
' Improvements in ACR-CRISS Scores Median CRISS Score * Composite score of change from baseline in mRSS, HAQ-DI, FVC % predicted, and physician and patient global assessments lm Anabasum (n=26) * MRSS represents largest weighted factor in x ACR-CRISS composite o @ Placebo (n=15) 8 - ACR-CRISS scores
Slide 18: Additional Efficacy Outcomes Favor Anabasum (Part 1)
' Additional Efficacy Outcomes Favor Anabasum (Part 1) *P<0.05 HAQ-DI, Change from Baseline Y FVC % Predicted, Change from Baseline >) 0.4 25 w w g a 2 2 215 5S E e 1 y a = 705 a re) of z 0 < € x= 205 = of & et S a é 5-15 + LR 0 4 8 12 16 Week Week —®-— Anabasum —®—Placebo —®— Anabasum —®~Placebo Re
Slide 19: Additional Efficacy Outcomes Favor Anabasum (Part 2)
Additional Efficacy Outcomes Favor Anabasum (Part 2) *P<0.05 MDGA, Change from Baseline (— PtGA, Change from Baseline ) 15 ws Ed a4 2 c § 8 E £05 4 4 > <0 9 £ + < 0.5 % : ga £ & * & es 0 4 8 12 16 Week Week —®- Anabasum —®~Placebo —®— Anabasum —®—Placebo Reduction = improvement \ Reduction = improve
Slide 20: Molecular Skin Score Improvement Compared to Placebo
Improvement Compared to Placebo x “Molecular Skin Score” in Skin Biopsies from Phase 2 Show ° Mathematical calculation of skin thickening based on gene expression - Based on expression levels of specific genes from microarray data - Validated in five independent SSc patient cohorts - Highly correlat
Slide 21: Ongoing Open-Label Extension of Phase 2 Study
x Ongoing Open-Label Extension of Phase 2 Study Interim Data Expected H2 2017 ° Open-label extension to collect long-term safety and efficacy data * 12-month duration, planning to extend to 24 months ° All subjects receive anabasum PHARMACEUTICALS
Slide 22: Planned Design of Upcoming Phase 3 Study
x Planned Design of Upcoming Phase 3 Study Phase 3 Study Scheduled to Commence H2 2017 ) * Double-blind, randomized, placebo-controlled Primary Endpoint: + Patient number: n = 270 multinational * Change from baseline in mRSS ° 52 week study Secondary Endpoints: * Dose: anabasum 20 mg BID; 5 mg BID,
Slide 23: Systemic Sclerosis Clinical Development Milestones
x Systemic Sclerosis Clinical Development Milestones * Oral presentation of Phase 2 data at » Launch Phase 3 study EULAR-17 «Interim data from open-label study « Extend duration of open-label study CORBUS 23
Slide 24: Cystic Fibrosis
Cystic Fibrosis: - Positive Phase 2 data - Support from the Cystic Fibrosis Foundation - Expected to commence Phase 2b study in H2 2017 CORBUS X PHARMACEUTICALS
Slide 25: Key Takeaways: Cystic Fibrosis
Key Takeaways Cystic Fibrosis CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. CF is characterized by chronic lung inflammation that leads to lung damage and fibrosis. Life-threatening, rare disease Inflammation and fibrosis play key role in CF morbidi
Slide 26: Inflammation: a Key Driver of CF Morbidity and Life-Span
"Inflammation: a Key Driver of CF Morbidity and Life-Span ° CFTR interacts with multiple actors in the inflammatory cascade? ° CF cell lines and animal models exhibit increased inflammation even in absence of any infection’ ° CFTR-blockers increase inflammation in vitro? ° Evidence of in utero infla
Slide 27: Anabasum is Uniquely Positioned in Cystic Fibrosis
x Anabasum is Uniquely Positioned in Cystic Fibrosis Potential to be First Approved Therapy Targeting Inflammation and Fibrosis in CF Resolution of Chronic Inflammation / Fibrosis in CF atmpeteas * Resolution of Inflammation / Fibrosis | | | | | hyperinflammation Anabasum » Reduction of pulmonary (C
Slide 28: Clinical Development of Anabasum in Cystic Fibrosis
x Clinical Development of Anabasum in Cystic Fibrosis ¢ Targeting all patients: mutation/pathogen/medication agnostic Positive data in Phase 2 study Well tolerated and not immunosuppressive Reduction in pulmonary exacerbations Reduction in inflammatory cells and mediators in sputum Expected to launc
Slide 29: Design of Completed Phase 2 Study
x Design of Completed Phase 2 Study Data Announced March 2017 Double-blind, randomized, placebo-controlled 21 clinical sites in the U.S. and Europe 85 adults ages 18 to 65 with CF 16 week study, 12 weeks of active dosing Eligibility criteria All mutations allowed FEV1 = 40% predicted Background medi
Slide 30: Safety and Tolerability Summary
x Safety and Tolerability Summary ° Anabasum was well tolerated ° No serious or severe anabasum-related TEAEs noted « Most common anabasum-related mild adverse event: - Dry mouth (mild, 13% vs 0% in placebo) PHARMACEUTICALS
Slide 31: Pulmonary Exacerbation Requiring Treatment with IV Antibiotics
Pulmonary Exacerbation Requiring Treatment with IV Antibiotics Rate of Pulmonary Exacerbations Requiring IV Antibiotics * Pulmonary exacerbations (PEx) captured as Weeks 1-4 Weeks 5-12 an event of special interest °° °° * PEx are respiratory or systemic symptoms 03 03 requiring new antibiotics 02 02
Slide 32: Pulmonary Exacerbations Treated with Any New Antibiotic
Pulmonary Exacerbations Treated with Any New Antibiotic Rate of Pulmonary Exacerbations Requiring New ° Abroader look at acute pulmonary a on exacerbations as defined by treatment with Weeks 1-4 Weeks 5-12 any new antibiotics for respiratory system 3 08 08 symptoms = 07 07 ; 1 x * : « Reduction from
Slide 33: FEV1 % Predicted Values Remained Stable Throughout Study
x FEV1 % Predicted Values Remained Stable Throughout Study LS Mean Change (SE) from Baseline ‘=== Placebo 7.5 ————Anabasum 2000 . === Anabasum 20 mg BID a £ g He 2.5 BE o x8 5. Fy 7.5 4 10 1 29 85 Days
Slide 34: Consistent Reduction in Key Inflammatory Biomarkers (Sputum)
x Consistent Reduction in Key Inflammatory Biomarkers (Sputum) Reduction in anabasum 20 mg BID compared to placebo (Log"°) Neutrophils, cells/ml p= 0.053 Eosinophils, cells/ml p= 0.089 Lymphocytes, cells/ml Macrophages, cells/ml ] Neutrophil elastase, meg/ml IL-8, pe/ml IgG, mg/dl 25 2 Least squares
Slide 35: Cystic Fibrosis Clinical Development Milestones
x Cystic Fibrosis Clinical Development Milestones v Positive topline results from Phase 2 * Expected launch of Phase 2b study study * Phase 2 data to be presented at * Oral presentation of Phase 2 data at NACFC-17 ECFS-17 CORBUS 35
Slide 36: Dermatomyositis & Systemic Lupus Erythematosus
Dermatomyositis & Systemic Lupus Erythematosus: - Dermatomyositis - Ongoing Phase 2 study - topline results expected H2 2017 - Ongoing open-label extension - NIH funded - Systemic Lupus Erythematosus - Launching Phase 2 study H2 2017 - NIH funded CORBUS PHARMACEUTICALS
Slide 37: Key Takeaways: Dermatomyositis
Key Takeaways Treated with immunosuppressive therapies, but with significant toxicities Dermatomyositis Chronic systemic autoimmune disease characterized by inflammation of skin and muscles ee U.S. + EU greet SKIN & MUSCLE Involvement can cause significant morbidity and mortality from interstitial l
Slide 38: Dermatomyositis Phase 2 Clinical Study
x Dermatomyositis Phase 2 Clinical Study Topline Results Expected H2 2017 } * Double-blind placebo control randomized study Primary Endpoints: * 1 site - University of Pennsylvania Perlman School | ° Safety/tolerability of Medicine * Change in skin activity using CDASI ° 22 adults with refractory sk
Slide 39: Dermatomyositis Open-Label Extension Underway
x Dermatomyositis Open-Label Extension Underway * Open-label extension to collect long-term safety and efficacy data ° 12-month open-label extension ° All subjects receive anabasum PHARMACEUTICALS
Slide 40: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Chronic systemic autoimmune disease characterized by arthritis, skin rashes, kidney disease, and involvement of the nervous system and other organs 500,000 — 600,000 Patients in the U.S. + EU ees ee 10-12:1 Women to Men PERT Higher Incidence and More Severe in Blacks and
Slide 41: Systemic Lupus Erythematosus Phase 2 Clinical Study
x Systemic Lupus Erythematosus Phase 2 Clinical Study Commence Patient Enrollment Expected H2 2017 * Double-blind, placebo controlled randomized study * 10 sites in the U.S. ° 100 adults with SLE * 16 week study, 12 weeks of active dosing * Dose response: 20 mg BID, 20 QID 5 mg QID, or placebo f pan
Slide 42: DM and SLE Clinical Development Milestones
x DM and SLE Clinical Development Milestones DM DM v¥ Complete enrollment of Phase 2 study Topline data from Phase 2 study SLE Start Phase 2 study CORBUS)y 42
Slide 43: Scientific Advisory and Principal Investigators
Scientific Advisory and Principal Investigators Scientific Advisors ‘THE UNIVERSITY of NORTH CAROLINA Michael Knowles, MD, PhD Al Principal Investigators 7 HOSPITAL FOR MS SPECIAL SURGERY Robert Spiera, MD US PI-SSc HARVARD Charles Serhan, PhD MEDICAL SCHOOL Christopher Denton, PhD, FRCP. Royal Free
Slide 44: Financial Profile: CRBP (NASDAQ)
x Financial Profile: CRBP (NASDAQ) Current Capital Funds Operations Through End of 2018 $78MM .2MM aised to-date $353MM 30.2 shares Ratsoa terest 1.1 ™ $49MM + Market cap* outstanding . Cash balance** (57.8MM fully diluted)** $20 M M dally volume non-dilutive funding from N.I.H. and CF Foundation *
Slide 45: Contact Us
CONTACT US Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 info@corbuspharma.com www.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062 45 a
Corbus Pharmaceuticals Holdings — Investor Presentation (June 2017) on 6ix